US2015157643A1PendingUtilityA1

Method for post coital contraception in overweight or obese female subjects using ulipristal acetate

41
Assignee: HRA PHARMA LABPriority: Feb 1, 2010Filed: Jan 9, 2015Published: Jun 11, 2015
Est. expiryFeb 1, 2030(~3.6 yrs left)· nominal 20-yr term from priority
A61P 15/18A61K 31/57
41
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides a method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese.

Claims

exact text as granted — not AI-modified
1 . A method for providing post coital contraception in a female subject, comprising providing the subject with a therapeutically effective amount of ulipristal acetate, wherein the female subject is overweight or obese. 
     
     
         2 . The method of  claim 1  wherein the female subject has a body mass index (BMI) above about 25. 
     
     
         3 . The method of  claim 1 , wherein the female subject has a body mass index (BMI) between about 25 and about 35. 
     
     
         4 . The method of  claim 1 , wherein the female subject has a body mass index (BMI) between about 25 and about 30. 
     
     
         5 . The method of  claim 1 , wherein the female subject has a body mass index (BMI) between about 30 and about 35. 
     
     
         6 . The method of  claim 1 , wherein the female subject has a body mass index (BMI) above about 35. 
     
     
         7 . The method of  claim 1 , wherein post coital contraception is provided within about 72 hours after unprotected intercourse. 
     
     
         8 . The method of  claim 1 , wherein post coital contraception is provided within about 120 hours after unprotected intercourse. 
     
     
         9 . The method of  claim 1 , wherein the post coital contraception is emergency contraception. 
     
     
         10 . The method of  claim 1 , wherein the ulipristal acetate is administered in an oral dosage form. 
     
     
         11 . The method of  claim 10 , wherein the oral dosage form is a tablet. 
     
     
         12 . The method of  claim 1  wherein the dosage form comprises about 30 mg ulipristal acetate.

Cited by (0)

No later patents cite this yet.

References (0)

No backward citations on record.